| Nom du produit | Linagliptin |
|---|---|
| Numéro CAS | 668270-12-0 |
| Formule moléculaire | C25H28N8O2 |
| Poids moléculaire | 472.54 g/mol |
| Apparence | Poudre cristalline blanche à blanc cassé |
| Essai (HPLC) | ≥99,01 TP3T |
| Perte au séchage | ≤0.5% |
| Résidu au feu | ≤0.1% |
| Métaux lourds | ≤ 10 ppm |
| Point de fusion | 196-202°C |
| Rotation spécifique | [α]D20 = +50° to +56° (c=1, methanol) |
Besoin d'aide ? Contacter notre équipe

Linagliptin is the DPP-4 inhibitor that doesn’t need a dose adjustment for kidney or liver function – and that’s a big deal for type 2 diabetes patients who often have comorbidities. Unlike many of its peers, it’s cleared primarily via bile and gut, so it’s a safer bet for long-term use in renally impaired patients. For formulators, that means a competitive edge in a crowded market: you can offer a once-daily, 5 mg tablet that works reliably without the monitoring headaches.
We supply linagliptin as a high-purity, crystalline API that meets or exceeds pharmacopoeial standards. Every batch is rigorously tested and shipped with a full COA, so you can move from development to production with confidence.
Room,5-0203, Courtyard 205, Lianhu District,Xi'an,Shaanxi,China